CD19 and acute lymphoblastic leukemia: In malignant B-cell cultures, including B-ALL and lymphoma lines, pre-treatment of CD19-directed CAR T-cells with Bcl-2 inhibitors such as venetoclax resulted in enhanced cellular longevity, increased cytokine secretion, and improved cytotoxic function.